The pro-apoptotic effect of quercetin in cancer cell lines requires ERβ-dependent signals

Journal of Cellular Physiology

Volumn 227, Issue 5, 2012, Pages 1891-1898

  Bulzomi, Pamela ^a   Galluzzo, Paola ^a,b   Bolli, Alessandro ^a   Leone, Stefano ^a   Acconcia, Filippo ^a   Marino, Maria ^a  

^a ROMA TRE UNIVERSITY   (Italy)

^b LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; ESTROGEN RECEPTOR BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN BCL 2; PROTEIN KINASE B; QUERCETIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; COLON CANCER; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTIOXIDANTS; APOPTOSIS; CELL LINE, TUMOR; CYCLIN D1; ENZYME ACTIVATION; ESTRADIOL; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; MALE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-BCL-2; PTEN PHOSPHOHYDROLASE; QUERCETIN; SIGNAL TRANSDUCTION;

EID: 84856185031     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22917     Document Type: Article

References (65)

1. Acconcia F, Totta P, Ogawa S, Cardillo I, Inoue S, Leone S, Trentalance A, Muramatsu M, Marino M. 2005. Survival versus apoptotic 17β-estradiol effect: Role of ERα and ERβ activated non-genomic signaling. J Cell Physiol 203: 193-201.
2. Ascenzi P, Bocedi A, Marino M. 2006. Structure-function relationship of estrogen receptor α and β: Impact on human health. Mol Aspects Med 27: 299-402.
3. Bai Z, Gust R. 2009. Breast cancer, estrogen receptor and ligands. Arch. Pharm (Weinheim) 342: 133-149.
4. Bolli A, Bulzomi P, Galluzzo P, Acconcia F, Marino M. 2010. Bisphenol A impairs estradiol-induced protective effects against DLD-1 colon cancer cell growth. IUBMB Life 62: 684-687.
5. Boots AW, Haenen GR, Bast A. 2008. Health effects of quercetin: From antioxidant to nutraceutical. Eur J Pharmacol 585: 325-337.
6. Burkitt DP, Walker AR, Painter NS. 1972. Effect of dietary fibre on stools and the transit-times, and its role in the causation of disease. Lancet 2: 1408-1412.
7. Caiazza F, Galluzzo P, Lorenzetti S, Marino M. 2007. 17β-estradiol induces ERβ up-regulation via p38/MAPK activation in colon cancer cells. Biochem Biophys Res Commun 359: 102-107.
8. Campbell-Thompson M, Lynch IJ, Bhardwaj B. 2001. Expression of estrogen receptor (ER) subtypes and ERβ isoforms in colon cancer. Cancer Res 61: 632-640.
9. Chiacchiera F, Simone C. 2008. Signal-dependent regulation of gene expression as a target for cancer treatment: Inhibiting p38α in colorectal tumors. Cancer Lett 265: 16-26.
10. Daskiewicz JB, Depeint F, Viornery L, Bayet C, Comte-Sarrazin G, Comte G, Gee JM, Johnson IT, Ndjoko K, Hostettmann K, Barron D. 2005. Effects of flavonoids on cell proliferation and caspase activation in a colonic cell line HT 29, SAR study. J Med Chem 48: 2790-2804.
11. De Stefani E, Boffetta P, Deneo-Pellegrini H, Mendilaharsu M, Carzoglio JC, Ronco A, Olivera L. 1999. Dietary antioxidants and lung cancer risk: A case-control study in Uruguay. Nutr Cancer 34: 100-110.
12. Dihal AA, de Boer VC, van der Woude H, Tilburgs C, Bruijntjes JP, Alink GM, Rietjens IM, Woutersen RA, Stierum RH. 2006. Quercetin, but not its glycosidated conjugate rutin, inhibits azoxymethane-induced colorectal carcinogenesis in F344 rats. J Nutr 136: 2862-2867.
13. Fitzpatrick JM, Schulman C, Zlotta AR, Schröder FH. 2009. Prostate cancer: A serious disease suitable for prevention. Br J Urol Int 103: 864-870.
14. Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O, Rice LW. 2000. Selective loss of estrogen receptor β in malignant human colon. Cancer Res 60: 245-248.
15. Galluzzo P, Caiazza F, Moreno S, Marino M. 2007. Role of ERβ palmitoylation in the inhibition of human colon cancer cell proliferation. Endocr Relat Cancer 14: 153-167.
16. Galluzzo P, Martini C, Bulzomi P, Leone S, Bolli A, Pallottini V, Marino M. 2009. Quercetin-induced apoptotic cascade in cancer cells: Antioxidant versus estrogen receptor α-dependent mechanisms. Mol Nutr Food Res 53: 699-708.
17. Gehm BD, McAndrews JM, Chien PY, Jameson JL. 1997. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA 94: 14138-14143.
18. Halliwell B, Zhao KC, Whiteman M. 2000. The gastrointestinal tract: A major site of antioxidant action? Free Radic Res 33: 819-830.
19. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Ström A, Treuter E, Warner M, Gustafsson J-Å. 2007. Estrogen receptors: How do they signal and what are their targets. Physiol Rev 87: 905-931.
20. Hogan AM, Collins D, Sheehan K, Zierau O, Baird AW, Winter DC. 2010. Rapid effects of phytoestrogens on human colonic smooth muscle are mediated by oestrogen receptor β. Mol Cell Endocrinol 320: 106-110.
21. Huang H, Cheville JC, Pan Y, Roche PC, Schmidt LJ, Tindall DJ. 2001. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J Biol Chem 276: 38830-38836.
22. Janakiram NB, Steele VE, Rao CV. 2009. Estrogen receptor-β as a potential target for colon cancer prevention: Chemoprevention of azoxymethane-induced colon carcinogenesis by raloxifene in F344 rats. Cancer Prev Res 2: 52-59.
23. Kim EK, Choi EJ. 2010. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 1802: 396-405.
24. Kim HP, Son KH, Chang HW, Kang SS. 2004. Anti-inflammatory plant flavonoids and cellular action mechanisms. J Pharmacol Sci 96: 229-245.
25. Kim JY, Kim EH, Park SS, Lim JH, Kwon TK, Choi KS. 2008. Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and proteasome-mediated c-FLIPS down-regulation. J Cell Biochem 105: 1386-1398.
26. Konstantinopoulos PA, Kominea A, Vandoros G, Sykiotis GP, Ricopoulos P, Varakis I, Sotiropoulou-Bonikou G, Papavassiliou AG. 2003. Oestrogen receptor β (ERβ) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur J Cancer 39: 1251-1258.
27. Kuiper GG, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, Gustafsson J-Å. 1997. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138: 863-870.
28. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson J-Å. 1998. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139: 4252-4263.
29. Kumar R, Verma V, Jain A, Rajeev K, Jagdamba J, Maikhuri P, Gupta G. 2010. Synergistic chemoprotective mechanisms of dietary phytoestrogens in a select combination against prostate cancer. J Nutr Biochem (in press).
30. Kuo SM. 1996. Antiproliferative potency of structurally distinct dietary flavonoids on human colon cancer cells. Cancer Lett 110: 41-48.
31. Kuo P-C, Liu H-F, Chao J-I. 2004. Survivin and p53 modulate quercetin-induced cell growth inhibition and apoptosis in human lung carcinoma cells. J Biol Chem 279: 55875-55985.
32. Kyle JA, Sharp L, Little J, Duthie GG, McNeill G. 2010. Dietary flavonoid intake and colorectal cancer: A case-control study. Br J Nutr 103: 429-436.
33. Lee JE, Safe S. 2000. 3', 4'-dimethoxyflavone as an aryl hydrocarbon receptor antagonist in human breast cancer cells. Toxicol Sci 58: 235-242.
34. Lee TJ, Kim OH, Kim S, Park JW, Kwon TK. 2006. Quercetin arrests G2/M phase and induces caspase-dependent cell death in cells. Cancer Lett 240: 234-242.
35. Legler J, van den Brink CE, Brouwer A, Murk AJ, van der Saag PT, Vethaak AD, van der Burg B. 1999. Development of a stably transfected estrogen receptor-mediated luciferase reporter gene assay in the human T47D breast cancer cell line. Toxicol Sci 48: 55-66.
36. Leung YK, Mak P, Hassan S, Ho SM. 2006. Estrogen receptor (ER)-β isoforms: A key to understanding ER-β signaling. Proc Natl Acad Sci USA 103: 13162-13167.
37. Manach C, Williamson G, Morand C, Scalbert A, Remesy C. 2005. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 81: 230S-242S.
38. Marino M, Acconcia F, Bresciani F, Weisz A, Trentalance A. 2002. Distinct nongenomic signal transduction pathways controlled by 17β-estradiol regulate DNA synthesis and cyclin D(1) gene transcription in HepG2 cells. Mol Biol Cell 13: 3720-3729.
39. Marino M, Acconcia F, Trentalance A. 2003. Biphasic estradiol-induced AKT phosphorylation is modulated by PTEN via MAP kinase in HepG2 cells. Mol Biol Cell 14: 2583-2591.
40. Matter WF, Brown RF, Vlahos CJ. 1992. The inhibition of phosphatidylinositol 3-kinase by quercetin and analogs. Biochem Biophys Res Commun 186: 624-631.
41. Mense SM, Hei TK, Ganju RK, Bhat HK. 2008. Phytoestrogens and breast cancer prevention: Possible mechanisms of action. Environ Health Perspect 116: 426-433.
42. Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, Su JL, Kliewer SA, Lehmann JM, Willson TM. 1998. Cloning and characterization of human estrogen receptor β isoforms. Biochem Biophys Res Commun 247: 75-78.
43. Murakami A, Ashida H, Terao J. 2008. Multitargeted cancer prevention by quercetin. Cancer Lett 269: 315-325.
44. Murota K, Terao J. 2005. Quercetin appears in the lymph of unanesthetized rats as its phase II metabolites after administered into the stomach. FEBS Lett 579: 5343-5346.
45. Nilsson S, Gustafsson J-Å. 2011. Estrogen receptors: Therapies targeted to receptor subtypes. Clin Pharmacol Ther 89: 44-55.
46. Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, Muramatsu M. 1998. Molecular cloning and characterization of human estrogen receptor βcx: A potential inhibitor of estrogen action in human. Nucleic Acids Res 26: 3505-3512.
47. O'Leary KA, Day AJ, Needs PW, Mellon FA, O'Brien NM, Williamson G. 2003. Metabolism of quercetin-7- and quercetin-3-glucuronides by an in vitro hepatic model: The role of human beta-glucuronidase, sulfotransferase, catechol-O-methyltransferase and multi-resistant protein 2 (MRP2) in flavonoid metabolism. Biochem Pharmacol 65: 479-491.
48. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J-Å, Kushner PJ, Scanlan TS. 1997. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 277: 1508-1510.
49. Saville B, Wormke M, Wang F, Nguyen T, Enmark E, Kuiper G, Gustafsson J-Å, Safe S. 2000. Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem 275: 5379-5387.
50. Shen YH, Zhang L, Gan Y, Wang X, Wang J, LeMaire SA, Coselli JS, Wang XL. 2006. Up-regulation of PTEN (phosphatase and tensin homolog deleted on chromosome ten) mediates p38 MAPK stress signal-induced inhibition of insulin signaling. A cross-talk between stress signaling and insulin signaling in resistin-treated human endothelial cells. J Biol Chem 281: 7727-7736.
51. Shirai M, Kawai Y, Yamanishi R, Kinoshita T, Chuman H, Terao J. 2006. Effect of a conjugated quercetin metabolite, quercetin 3-glucuronide, on lipid hydroperoxide-dependent formation of reactive oxygen species in differentiated PC-12 cells. Free Radic Res 40: 1047-1053.
52. Singh SU, Casper RF, Fritz PC, Sukhu B, Ganss B, Girard BJr, Savouret JF, Tenenbaum HC. 2000. Inhibition of dioxin effects on bone formation in vitro by a newly described aryl hydrocarbon receptor antagonist, resveratrol. J Endocrinol 167: 183-195.
53. Stevenson DE, Hurst RD. 2007. Polyphenolic phytochemicals-just antioxidants or much more? Cell Mol Life Sci 64: 2900-2916.
54. Surh YJ, Kundu JK, Na HK, Lee JS. 2005. Redox sensitive transcription factors as prime targets for chemoprevention with anti-inflammatory and antioxidative phytochemicals. J Nutr 135: 2993S-3001S.
55. Totta P, Acconcia F, Virgili F, Cassidy A, Weinberg PD, Rimbach G, Marino M. 2005. Daidzein-sulfate metabolites affect transcriptional and antiproliferative activities of estrogen receptor-β in cultured human cancer cells. J Nutr 135: 2687-2693.
56. van der Woude H, Gliszczyńska-Swigło A, Struijs K, Smeets A, Alink GM, Rietjens IM. 2003. Biphasic modulation of cell proliferation by quercetin at concentrations physiologically relevant in humans. Cancer Lett 200: 41-47.
57. van der Woude H, Ter Veld MG, Jacobs N, van der Saag PT, Murk AJ, Rietjens IM. 2005. The stimulation of cell proliferation by quercetin is mediated by the estrogen receptor. Mol Nutr Food Res 49: 763-771.
58. van Erk MJ, Roepman P, van der Lende TR, Stierum RH, Aarts JM, van Bladeren PJ, van Ommen B. 2005. Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur J Nutr 44: 143-156.
59. Vijayababu MR, Arunkumar A, Kanagaraj P, Venkataraman P, Krishnamoorthy G, Arunakaran J. 2006. Quercetin downregulates matrix metalloproteinases 2 and 9 proteins expression in prostate cancer cells (PC-3). Mol Cell Biochem 287: 109-116.
60. Wada-Hiraike O, Imamov O, Hiraike H, Hultenby K, Schwend T, Omoto Y, Warner M, Gustafsson J-Å. 2006. Role of estrogen receptor β in colonic epithelium. Proc Natl Acad Sci USA 103: 2959-2964.
61. Wagner EF, Nebreda AR. 2009. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9: 537-549.
62. Warner M, Gustafsson J-Å. 2010. The role of estrogen receptor β (ERβ) in malignant diseases- a new potential target for antiproliferative drugs in prevention and treatment of cancer. Biochem Biophys Res Commun 396: 63-66.
63. Williams RJ, Spencer JPE, Rice-Evans C. 2004. Flavonoids: Antioxidants or signalling molecules? Free Rad Biol Med 36: 838-849.
64. Wong NA, Malcomson RD, Jodrell DI, Groome NP, Harrison DJ, Saunders PT. 2005. ERβ isoform expression in colorectal carcinoma: An in vivo and in vitro study of clinicopathological and molecular correlates. J Pathol 207: 53-60.
65. Yue H, Yang B, Zhang H, Zhu SD, Du XJ, Feng XL, Yu Z, Xia YT, Yu JP. 2002. Clinical significance of TGF-β1 and β-glucuronidase synchronous detection in human pancreatic cancer. Hepatobiliary Pancreat Dis Int 1: 309-311.